Clinical Practice Guidelines The Egyptian clinical practice guidelines diagnosis management metabolic associated fatty liver disease Yasser Fouad Gamal Esmat1 Reda Elwakil2 Serag Zakaria1 Ayman Yosry1 Imam Waked3 Maissa ElRazky1 Wahid Doss1 Magdy ElSerafy1 Ebraheem Mostafa4 Mahmood Anees5 Mohamed A Sakr2 Nadia AbdelAty2 Ashraf Omar1 Samy Zaki7 Amgad Alzahaby7 Hamdy Mahfouz8 Maysaa Abdalla9 Mahmoud Albendary10 AbdelKhalek Hamed11 Ahmed Gomaa12 Adel Hasan13 Sherif Abdelbaky6 Medhat El sahhar14 Gamal Shiha15 Dina Attia16 Writing team Egyptian MAFLD Research Group EMRG Ebada Saeed17 Enas Kamal Shamardan Bazeed18 Mai Mehrez19 Shereen Abdelaleem1 Yasmine Gaber1 Mohammed Abdallah20 Asmaa Salama16 Doaa A Tawab21 Shaymaa Nafady16 Department Gastroenterology Hepatology Endemic Medicine Faculty Medicine Minia University 1Department Endemic Medicine Hepatology Faculty Medicine Cairo University Cairo 2Tropical Medicine Department Faculty Medicine Ain Shams University 3Department Hepatology Gastroenterology National Liver Institute Menoufia University Shebeen El Kom 4Theodore Bilharz Research institute Cairo 5Department Gastroenterology Hepatology 6Gastroenterology Hepatology Endemic Medicine Faculty Medicine Tanta University Tanta 7Department Hepatogastroenterology Infectious Diseases AlAzhar University Cairo 8Department Hepatogastroenterology Infectious Diseases AlAzhar University Assuit 9Department Gastroenterology Hepatology Endemic Medicine Faculty Medicine Zagazig University Zagazig 10Department Gastroenterology Hepatology Endemic Medicine Faculty Medicine Mansura University Mansura 11Department Internal Medicine Hepatology Diabetes Egyptian Military Medical Academy Cairo 12Department Gastroenterology Hepatology Endemic Medicine Faculty Medicine Fayoum University Fayoum 13Department Gastroenterology Hepatology Endemic Medicine Faculty Medicine Suez Canal University Suez 14Egyptian Association Study Liver Gastrointestinal Disease EASLGD Police Medical Academy Cairo 15Hepatology Gastroenterology Unit Internal Medicine Department Faculty Medicine Mansoura University Mansoura 16Department Gastroenterology Hepatology Infectious Diseases Faculty Medicine BeniSuef University Beni Suef 17Department Gastroenterology Hepatology Infectious Diseases Faculty Medicine Benha University Benha 18Department Tropical Medicine Gastroenterology Faculty Medicine South Valley University Qena 19Department Hepatology NTHMRI Cairo 20Department Medical Research Division Medicine National Research Centre Giza 21Department Tropical Medicine Gastroenterology Faculty Medicine Assuit University Assuit Egypt Abstract The landscape chronic liver disease Egypt drastically changed past decades The prevalence metabolicassociated fatty liver disease MAFLD risen alarming levels Despite magnitude problem regional guidelines developed tackle disease This document provides clinical practice guidelines key Egyptian opinion leaders MAFLD screening diagnosis management covers aspects management MAFLD The document considers Address correspondence Dr Yasser Fouad Professor Gastroenterology Hepatology Infectious Diseases Faculty Medicine Minia University Minia 61519 Egypt Email Yasserabdallahmuedueg Submitted 01Jul2021 Revised 24Oct21 Accepted 31Oct2021 Published 25Jan2022 Access article online Quick Response Code Website wwwsaudijgastrocom DOI 104103sjgsjg_357_21 This open access journal articles distributed terms Creative Commons AttributionNonCommercialShareAlike 40 License allows remix tweak build work noncommercially long appropriate credit given new creations licensed identical terms For reprints contact WKHLRPMedknow_reprintswolterskluwercom How cite article Fouad Y Esmat G Elwakil R Zakaria S Yosry A Waked I et al The Egyptian clinical practice guidelines diagnosis management metabolic associated fatty liver disease Saudi J Gastroenterol 202228320 2022 Saudi Journal Gastroenterology Published Wolters Kluwer Medknow 3 local situations burden clinical management healthcare sector proposed daily clinical practical use Particular reference special groups necessary Keywords Egyptian guidelines MAFLD INTRODUCTION EPIDEMIOLOGY The landscape chronic liver disease Egypt drastically changed past decades decreasing prevalence viral hepatitis increasing prevalence metabolicassociated fatty liver disease MAFLD known nonalcoholic fatty liver disease NAFLD MAFLD risen prevalence alarming levels placing enormous burden individuals healthcare systems Despite magnitude problem regional guidelines developed tackle disease This document provides clinical practice guidelines key Egyptian opinion leaders MAFLD screening diagnosis management The participants performed detailed systematic review literature retrieved extensive PubMed search March 2021 particular domains deciphered current scientific evidence simple practice guidelines recommendations improve routine clinical practice patients MAFLD These guidelines cover aspects management MAFLD including epidemiology screening diagnosis evaluation treatment The statements guideline according Grading Recommendation Assessment Development Evaluation approach1 In case disagreement final grading evidence recommendations determined majority vote The document considers local situations burden clinical management healthcare sector proposed daily clinical practical use orchestrate advancing knowledge research MAFLD Particular reference special groups necessary The ultimate goal improve awareness MAFLD patient care encourage dialogue stakeholders development health policies assist decisionmaking process providing evidencebased data In addition identified areas gap knowledge set agenda calling research studies Egyptian population As expected new evidence emerge Egyptian cohorts updates guidelines required future Over past decades nutrition pattern Egyptian population witnessed overall increase energy intake Nutrition moved type diet increases intake fast food red meat vegetable oils processed foods soft drinks decrease intake fresh fruits vegetables2 It estimated 40 fat consumed women Egypt saturated fat3 rates low intake servings day fresh fruit vegetables Egypt 80 4 In contrast Egypt track meet World Health Organization WHO recommendations elimination hepatitis C dramatic decline number hepatitis C virus HCV cases56 Therefore profile liver disease Egypt witnessing trajectory shift communicable noncommunicable diseases79 Parallel changes prevalence overweight obesity bodymass index BMI 25 m²or greater risen globally 1980 2013 men 288 369 women 298 380 largest increases rate obesity worldwide seen Egypt10 Indeed Egypt 10 countries highest levels obesity worldwide 712 adult men overweight 264 obese 794 adult women overweight 484 obese10 Worryingly prevalence rates overweight obesity school children adolescents 315 127 respectively boys 20 years 395 144 respectively girls age group11 Similarly average prevalence insufficient physical activity Egypt 310 higher global prevalence 275 This number higher females 388 males 23210 The prevalence MAFLD risen parallel aforementioned changes direct clinical economic burden Although scant data magnitude MAFLD Egypt available data suggest Egypt highest prevalence MAFLD affecting onethird population compared global prevalence 2591213 Specific studies suggest prevalence range MAFLD Egypt approximately 475 567 having fibrosis14 present 4 Saudi Journal Gastroenterology Volume 28 Issue 1 JanuaryFebruary 2022 Fouad et al Egyptian MAFLD guidelines approximately 158 children15 Another retrospective study 2097 patients large Egyptian tertiary care liver centers revealed leading cause patient presentation MAFLD 44916 Unfortunately awareness patients physicians Egypt magnitude problem risks sufficient1718 Therefore surprising NAFLD seriously underdiagnosed realworld settings1920 patients diagnosed incidentally cirrhosis developed21 DEFINITION AND DIAGNOSIS OF MAFLD According Middle East North Africa consensus22 Egyptian guidelines endorse proposal international consensus panel redefinition fatty liver disease2325 The diagnosis MAFLD based presence liver steatosis detected liver histology imaging noninvasive biomarkers presence criteria include ⅰ overweight obesity ⅱ type 2 diabetes mellitus T2DM ⅲ clinical evidence metabolic dysfunction An avalanche evidence supports superiority new definition compared old NAFLD definition2629 In addition simplicity criteria render suitable resourceconstrained settings22272932 Figure 1 NATURAL HISTORY OF MAFLD Egypt highest global agestandardized death rate cirrhosis years 1990 2017 1033 100000 despite 224 decrease 199033 This decrease likely driven rapid decrease HCV death rate The decline expected continue 5 years However actual burden MAFLD Egypt fully characterized Alarming numbers emerging In 2017 128 deaths cirrhosis Egypt caused MAFLD 65 caused causes likely undiagnosed MAFLD In addition agestandardized prevalence rates compensated decompensated cirrhosis MAFLD 100000 increased 3123 194 1990 340 26 2017 respectively Furthermore proportion causes disabilityadjusted life years timebased measure combines years life lost premature mortality caused MAFLDrelated cirrhosis 2017 1233 MAFLDrelated HCC globally increase 898 1990 201735 Consistently study Egypt showed annual proportions MAFLDrelated HCC increased significantly 43 2010 206 2020 HCVrelated HCC declined 948 76736 Compared liver diseases recent study showed MAFLDrelated HCC significantly higher percentage death 1 year diagnosis approximately 5 months shorter survival time HCC related viral hepatitis HCVhepatitis B virus HBV37 Notably 2018 metaanalysis demonstrated noncirrhotic patients MAFLD 261 increased risk HCC compared etiologies liver disease38 Similarly MAFLD rapidly growing indication liver transplantation multiple countries region39 example 63 referred patients liver transplantation Kuwait 20182019 MAFLDrelated cirrhosis40 Though expected Egypt similar trend studies required confirm EXTRAHEPATIC MANIFESTATIONS OF MAFLD MAFLD multisystem disease associated plethora extrahepatic manifestations comorbidities41 MAFLD associated cardiovascular disease CVD41 chronic kidney disease CKD42 risk In addition liver cancer MAFLD implicated risk extrahepatic cancers43 CVD malignancy represent main causes death MAFLD patients44 baseline liver fibrosis strongest predictor4546 Therefore physicians treating patients MAFLD encouraged evaluate undertake risk factor comorbidities management holistic approach patient care CVD risk assessed risk scores atherosclerotic cardiovascular disease risk estimator MAFLD patients history cardiovascular event presenting clinically active CVD evidence metabolic comorbidities andor severe liver disease referred evaluation cardiologist evaluation Otherwise patients negative assessed having low CVD risk reevaluated 23 years47 MAFLD currently progressively increasing main cause hepatocellular carcinoma HCC globally 34 The available data suggest Egypt highest increases agestandardized incidence rate The types choice medications treatment T2DM hypertension dyslipidemia scope recommendations followed according specific disease guidelines Saudi Journal Gastroenterology Volume 28 Issue 1 JanuaryFebruary 2022 5 Fouad et al Egyptian MAFLD guidelines Figure 1 The Egyptian guidelines recommended algorithm diagnose MAFLD suspected patients evaluation management monitoring disease severity approach confirmed subjects The proposed model primary carebased multidisciplinary care model MAFLD initial identification cases mainly occur primary care attached appropriate referral pathway specialist care illustrated Recommendations MAFLD patients evaluated CVD referred cardiologist needed A1 Consideration extrahepatic manifestations MAFLD recommended B1 SCREENING FOR MAFLD Screening MAFLD ultrasonography recommended atrisk populations including overweight obesity T2DM metabolic dysfunction Patients MAFLD evaluated presence metabolic comorbidities T2DM hypertension dyslipidemia treated appropriately Recommendations Screening MAFLD ultrasonography recommended atrisk populations including T2DM metabolic dysfunction A1 Patients MAFLD evaluated presence metabolic comorbidities T2DM hypertension dyslipidemia treated appropriately reduce risk cardiovascular kidney disease A1 6 Saudi Journal Gastroenterology Volume 28 Issue 1 JanuaryFebruary 2022 Fouad et al Egyptian MAFLD guidelines NONINVASIVE TESTS Noninvasive modalities clinical practice needed diagnosis MAFLD assessing disease severity monitoring disease progression treatment response48 In routine clinical practice abdominal ultrasonography commonly usually sufficient detection hepatic steatosis49 However poor sensitivity detecting mild levels steatosis The controlled attenuation parameter CAP sensitive ultrasonography increasingly utilized assess liver fat obtained simultaneously liver stiffness measurement LSM vibrationcontrolled transient elastography VCTE FibroScan50 The optimal cutoff identifying fatty liver CAP suggested earlier metaanalysis 248 dBm50 However subsequent studies suggested higher optimal cutoff points 288 dBM51 302 dBM51 Further studies Egyptian population required In addition interquartile range 3040 dBm suggested associated reliable CAP measurements5152 Probe selection influences CAP values optimal cut points diagnosis fatty liver lower M probe versus XL probe53 MRIbased techniques MRIPDFF protonmagnetic resonance spectroscopy MRIMRS detect small amounts liver fat considered gold standard quantify liver fat Currently main indication liver fat fraction measurement MRI clinical trials54 Numerous steatosis simple scores proposed alternative method assessment hepatic steatosis particularly largepopulation studies In particular FLI includes BMI waist circumference triglycerides GGT widely used55 recently validated large cohort 35335 patients MAFLD56 Simple fibrosis scores involve clinical routine laboratory parameters widely validated reproducible scores inexpensive include aspartate aminotransferase ASTtoplatelet ratio index APRI57 Fibrosis4 index FIB4 58 NAFLD fibrosis score NFS59 Patients defined low high risk advanced fibrosis score according following cutoffs APRI 05 15 FIB4 130 267 NFS 1455 067611 These cutoffs need validated Egyptian cohorts These scores suited use initial assessment primarycare resourcepoor settings6061 Subjects indeterminant results high scores referred specialists evaluation appropriately guide management patients Proprietary biomarkers fibrosis include Nterminal type III collagen propeptide ProC3 A ProC3 based algorithm ADAPT algorithm includes age T2DM platelet count shown high diagnostic accuracy advanced fibrosis tertiary hospitals62 general lowrisk populations cohorts63 Liver stiffness measurement LSM obtained VCTE commercially available FibroScan increasingly Egypt An M probe XL probe available The majority MAFLD patients achieve successful measurement XL probe6465 The quality criteria guide use minimum 10 measurements 60 valid ratio median valid LSM IQR exceed 03 Magnetic resonance elastography higher accuracy success rates compared VCTE wider use limited availability cost6667 The combination LSM simple fibrosis scores advantage increasing accuracy decreasing percentage patients classified gray zone In contrast robust biomarker steatohepatitis Recommendations Noninvasive modalities clinical practice needed diagnosis MAFLD assessing disease severity monitoring disease progression treatment response A1 Abdominal ultrasonography recommended firstline tool detection hepatic steatosis A1 Controlled attenuation parameter CAP measurement sensitive tool ultrasonography Thus available diagnosis disease monitoring B1 Although considered gold standard quantify liver fat MRIbased techniques recommended routine clinical practice A1 The exclusion high risk significant fibrosis acceptable simple noninvasive biomarkers scores fibrosis A2 The confirmation significant fibrosis liver stiffness measurement VCTE andor sequential combination serum biomarkersscores A2 As clinical judgment liver biopsy required cases particularly patients indeterminant gray range scores B2 There strong biomarker steatohepatitis liver biopsy remains diagnostic test choice A1 Saudi Journal Gastroenterology Volume 28 Issue 1 JanuaryFebruary 2022 7 Fouad et al Egyptian MAFLD guidelines LIVER BIOPSY With high prevalence MAFLD biopsy evaluation indicated mainly confirm diagnosis clinical picture atypical aid assessment prognosis cases fall gray zone68 identify additional causes liver disease determine patient benefit intervention The use 16G wider needle percutaneous approach ultrasound guidance recommended biopsy An adequate histology specimen comprise 10 portal tracts 2 cm long Liver biopsy limited sampling error b interobserver variability c potentially rare complications69 There common systems evaluate MAFLD biopsies Brunt score70 NAFLD activity score NAS71 fatty liver inhibition progression FLIP algorithm steatosis activity fibrosis SAF scoring Emerging evidence suggests SAF score provides robust histological assessment72 Recommendations Indications liver biopsy patients MAFLD A1 A typical feature noninvasive tests sowing indeterminate unreliable results Assessment dualetiology liver diseases E t h c l l y p p r o v e d r e s e r c h o r clinical trials including bariatric surgery cholecystectomy Liver biopsy reporting standardized FLIP algorithm SAF score NASH CRN B1 MAFLDRELATED CIRRHOSIS steatosis hepatic imaging considered having MAFLDrelated cirrhosis absence hepatic steatosis typical histology MAFLD time presentation24 Cirrhosis diagnosed classic findings ultrasonography diagnosis missed obscured liver fat In context liver stiffness measurement LSM diagnose cirrhosis provide prognostic information MAFLD patients appropriate clinical context76 mortality rate higher increasing LSM77 If LSM available fibrosis scores initial step rule patients likely advanced fibrosis cirrhosis determine patients need referral LSM68 Aside prevention treatment decompensation events cirrhosis management focus education lifestyle modification protecting liver injury vaccination viral hepatitis avoidance hepatotoxic medications care coordination78 remains critical avoid sarcopenia Figure 2 Recommendations Patients cirrhosis absence current steatosis meet following criteria considered having MAFLDrelated cirrhosis Past present evidence meeting criteria diagnose MAFLD following 1 Historical documentation MAFLD previous liver biopsy 2 Historical documentation hepatic steatosis imaging B2 History past viral hepatitis considered patients dual disease etiology The highest risk hepatic complication cirrhosis nonhepatic complication patients stage 3 fibrosis4673 Classification cirrhosis depends prognostic stagingcompensated decompensated cirrhosis7475based presence absence clinically evident decompensating events jaundice variceal hemorrhage ascites spontaneous bacterial peritonitis encephalopathy Patients cirrhosis past present evidence metabolic dysfunction meet criteria diagnose MAFLD documentation MAFLD previous liver biopsy historical documentation DIAGNOSIS AND MONITORING FOR CLINICALLY SIGNIFICANT PORTAL HYPERTENSION AND VARICES The initial consequence liver cirrhosis general MAFLDrelated cirrhosis particular portal hypertension79 The goldstandard assessment clinically significant portal hypertension direct measurement HVPG invasive readily available Alternatively ultrasound feasible safe technique detecting morphological abnormalities associated cirrhosis indicative measure clinically significant portal hypertension Computed tomography CT MRI alternative tools80 8 Saudi Journal Gastroenterology Volume 28 Issue 1 JanuaryFebruary 2022 Fouad et al Egyptian MAFLD guidelines Figure 2 The Egyptian guidelines recommended algorithm evaluate manage patients MAFLDrelated compensated decompensated cirrhosis Patients MAFLDrelated cirrhosis screened gastroesophageal varices according Baveno VI criteria prognosis worse gastroesophageal varices compared without8182 The Baveno VI criteria recently validated patients MAFLD related cirrhosis83 Esophagogastroduodenoscopy EGD required confirm existence size varices invasive procedure risk bleeding84 The assessment LSM alternative accepted technique rule highrisk varices patients compensated cirrhosis The interpretation LSM data follows LSM 15 kPa diagnose cirrhosis LSM 1015 kPa suggestive cirrhosis LSM 10 kPa absence clinical signs rules cirrhosis8586 Patients LSM 15 kPa considered surveillance HCC LSM 2025 kPa andor thrombocytopenia use EGD recommended confirmation diagnosis prophylactic interventions patients85 Recommendations Screening EGD gastroesophageal varices recommended patients MAFLDassociated cirrhosis previously diagnosed treated B2 The exact interval screening EGD patients gastroesophageal varices unclear However patients multiple etiologies state decompensation continues screening EGD repeated year For rest patients screening intervals extended 2 years C2 R e l y n g o n n o n n v s v e t o diagnose g astroesophageal varices recommended low diagnostic accuracy A1 t e s t s Ultrasound recommended detecting cirrhosis Liver stiffness measurement transient elastography exclude highrisk varices patients compensated cirrhosis B2 Saudi Journal Gastroenterology Volume 28 Issue 1 JanuaryFebruary 2022 9 Fouad et al Egyptian MAFLD guidelines SCREENING FOR HCC IN PATIENTS WITH MAFLD Abdominal ultrasound preferred screening tool HCC availability costeffectiveness318788 However low sensitivity detection earlystage HCC 4789 simultaneous measurement serum biomarker AFP recommended8990 Despite high diagnostic efficacy dynamic imaging contrastenhanced ultrasonography computed tomography MRI screening HCC recommended surveillance modality lack wide availability high cost patients ultrasound quality suboptimal obesity excessive gas alimentary tract confirmation required91 A 6month screening interval recommended based tumor volume doublingtime HCC92 A randomized controlled trial demonstrated detection rate early HCC prognosis differ significantly 3 6monthly surveillance intervals 6monthly surveillance interval better 12month interval93 The targeted population screening MAFLD patients cirrhosis Although noncirrhotic patients MAFLD high risk HCC94 overall risk absence cirrhosis relatively low justify recommendation screening group patients particularly high prevalence MAFLD Recommendations Screening HCC MAFLD patients cirrhosis combination abdominal ultrasound alphafetoprotein AFP 6 months recommended improves overall survival recommended noncirrhotic patients lack evidence costeffectiveness A1 Computed tomography magnetic resonance imaging needed ultrasound quality inadequate B2 NONPHARMACOLOGICAL MANAGEMENT OF MAFLD Lifestyle modifications including dietary change weight loss exercise intervention remain cornerstone therapy firstline disease Diet Lifestyle Changes In patients MAFLD lifestyle intervention programs weight loss effectively lead reduction hepatic steatosis resolution steatohepatitis regression fibrosis improve patients quality life dosedependent manner The overall aim lifestyle intervention gradual weight loss 1 kgweek losing 710 body weight obese patients 5 nonobese subjects primary target There robust evidence support particular dietary approach patients MAFLD Generally hypocaloric diet 5001000kcal deficit daily protein intake 1215 gkg body weightday recommended Notably excess caloric restriction avoided exacerbate risk sarcopenia poor predictor outcome obese cirrhotic patients Dietary plans discourage consumption fructose encourage adopting Mediterranean type diet95 regular coffee drinking96 In real life weight loss critically sustaining effect challenging Using 5 As model ask advise assess assist arrange useful assess patients needs modify behavior Increasing clinic visit frequency97 andor utilizing internetbased approach lifestyle changes98 proposed maximize efficacy weight loss programs patients MAFLD Recent evidence suggests alcohol use associated hepatic steatosis subjects presumed NAFLD according current definitions99 In addition alcohol intake limits current definition reported increase significantly risk progression fatty liver disease23100101 increased risk HCC102103 Exercise Regular physical activity exercise demonstrated beneficial effects entire spectrum MAFLD including improvements hepatic steatosis healthrelated quality life104 reduction liver stiffness portal hypertension105 risk HCC106 There defined optimal frequency intensity duration type physical activityexercise induction resolution MAFLD For general adult population physical activity guidelines recommend total 150 minweek moderateintensity exercise 30 minday 5 daysweek vigorousintensity exercise 75 minweek 20 minday 3 days week Resistance exercise 23 daysweek flexibility exercises 2 daysweek recommended107 10 Saudi Journal Gastroenterology Volume 28 Issue 1 JanuaryFebruary 2022 Fouad et al Egyptian MAFLD guidelines A recent randomized clinical trial demonstrated vigorous moderate exercise aerobic resistance exercise reduces hepatic steatosis equally MAFLD effect appeared largely mediated weight loss108109 Thus generally selection type duration exercise tailored according patients preference likelihood compliance Resistance moderate exercise feasible aerobic vigorous exercise MAFLD patients poor fitness Combined dietexercise strategies containing minimum 6 months highintensity lifestyle intervention followed 1 year maintenance program recommended Recommendations Lifestyle changes including combined healthy diet exercise strategies effective normalization liver enzymes levels improvement liver histology B1 Weight loss beneficial recommended patients MAFLD regardless BMI 710 5 weight loss target overweight obese nonobese patients MAFLD respectively B1 Physical activity pharmacotherapy MAFLD patients steatohepatitis fibrosis B1 There particular mandatory dietary approach dietary counseling individualized Generally energy restriction Mediterraneantype diet regular coffee drinking avoiding processed food fructose advisable B1 Both vigorous moderate exercise aerobic exercise resistance training reduce hepatic steatosis equally MAFLD resistance exercise feasible patients poor fitness Recommendations individualized based patient preferences enhance longterm adherence B2 BARIATRIC AND METABOLIC THERAPIES ENDOSCOPIC APPROACHES AND SURGERY FOR MAFLD Though indication se MAFLD exists 6590 patients undertake weight loss surgery110111 Multiple retrospective prospective observational cohort studies Egypt112113 showed consistent results international findings metaanalyses114116 suggesting resolution hepatic steatosis steatohepatitis fibrosis observed 75 patients117 Special precautions required bariatric surgery considered patients MAFLDrelated cirrhosis high perioperative risk suggested operative mortality 163 decompensated disease118 Notably recent Egyptian study 132 cases ChildA MAFLDrelated cirrhosis laparoscopic sleeve gastrectomy LSG safe led improvement steatosis steatohepatitis fibrosis 30month followup119 The utility endoscopic bariatric metabolic therapies EBMT including intragastric balloons IGBs endoscopic sleeve gastroplasty ESG invasive safer interventions compared traditional operations emerging represent attractive option patients MAFLD120 Therefore based current evidence bariatric surgery offered patients MAFLD following criteria met 1 BMI 40 kgm2 BMI 35 kgm2 obesityrelated comorbidities 2 absence decompensated cirrhosis evidence concomitant portal hypertension The utility feasibility bariatric surgery patients MAFLD BMI 35 kgm2 currently unclear studies required clarify aspect Recommendations Bariatric surgery offered patients MAFLD following criteria met 1 BMI 40 kgm2 BMI 35 kgm2 obesityrelated comorbidities 2 absence decompensated cirrhosis evidence concomitant portal hypertension B1 The utility feasibility bariatric surgery patients MAFLD BMI 35 kgm2 currently unclear C2 Bariatric metabolic surgery improves MAFLD parameters including reduction liver fat resolution steatohepatitis regression fibrosis B1 The decision offering bariatric metabolic surgery patients cirrhosis individualized high risk postoperative complications C1 PHARMACOLOGICAL TREATMENT Due shared pathogenic pathways MAFLD Saudi Journal Gastroenterology Volume 28 Issue 1 JanuaryFebruary 2022 11 Fouad et al Egyptian MAFLD guidelines T2DM antidiabetic medications investigated treatment patients MAFLD121122 The beneficial effects pioglitazone hepatic histology patients T2DM reported smallrandomized controlled trials123127 However multiple possible concerns pioglitazone including weight gain edema development bladder cancer decrease bone mineral density therapy widely used128129 Metformin improve hepatic histology patients MAFLD130133 However improves insulin resistance130132133 reduces risk HCC patients noted studies randomized prospective134135 Though studies shown vitamin E role improving hepatic histology patients steatohepatitis123136138 studies failed confirm findings127132139140 A recent study demonstrated vitamin E decreases risk hepatic decompensation transplant death MAFLD patients bridging fibrosis cirrhosis141 The development prostate cancer hemorrhagic stroke possible concern vitamin E therapy142 Although statins beneficial effects hepatic histology143 reduce cardiovascular morbidity patients MAFLD143144 Thus statins safely patients MAFLD hyperlipidemia Obeticholic acid OCA firstinclass selective farnesoid X receptor FXR agonist represents advanced drug development date approved yet145 In terms adverse events main adverse event OCA pruritus occurred half patients received 25 mg daily Another major caveat OCA elevation serum lowdensity lipid protein LDL decrease highdensity lipid protein HDL Thus statins considered patients MAFLD hyperlipidemia receive OCA therapy145 There pharmacological agents clinical trials phase II phase III development Table 1 scope discussion guideline document Recommendations Statins reduce cardiovascular morbidity mortality patients receive obeticholic acid needed B1 Vitamin E improve histological markers disease activity concerns safety B2 Table 1 Pharmacological agents trials NAFLDNASH Phase Drug Target FXR agonist SCDI inhibitor Pan PAPAR agonist FXR agonist FXR agonist PPAR αβ agonist PPAR αγ agonist DGAT1 inhibitor FASN inhibitor FGF 21 analog FG19 analog Galactin 3 inhibitor Antibody LOX 21 Obtecholic acid Aramchol Lanifibrinor Tropixefor Gilofexor GS 9674 Elfibrinor Saroglitazar Pradigastat TVB 2640 Pegbelfermin NGM 282 Belapectin Simtuzumab DGAT1 diacylglycerol acyltransferase 1 FASn fatty acid synthase FGF21 fibroblast growth factor 21 FXR farnesoid X receptor LOXL2 lysyl oxidaselike 2 liver X receptor PPAR peroxisome proliferative activated receptor SCD1 steroylcoA desaturase 1 lll lll ll Ll ll ll ll ll ll ll ll ll ll Pioglitazone improves histological markers MAFLD concerns safety B2 Metformin effect hepatic histology improves insulin resistance reduce risk HCC B2 MONİTORİNG PROGRESS AND RESPONSE TO TREATMENT Given severity fibrosis major determinant hepaticrelated outcomes mortality146 significant fibrosis need closest monitoring following scheme recommended mainly undertaken primary care stage early fibrosis simple noninvasive scores fibrosis Interval followup 1 Patients fibrosis monitored 2 3year intervals concomitant metabolic risk factors worsening comorbidities 2 Patients fibrosis evidence uncontrolled concomitant metabolic risk factors monitored annual basis 3 Patients cirrhosis undergo monitoring 6month intervals including surveillance HCC section details Method followup With acknowledgment fact ideal biomarker score high predictive value differentiating different stages liver fibrosis recommend monitoring fibrosis progression clinic noninvasive scores NFS FIB4 ideally possible combination liver stiffness measurement 12 Saudi Journal Gastroenterology Volume 28 Issue 1 JanuaryFebruary 2022 Fouad et al Egyptian MAFLD guidelines transient elastography147148 increase accuracy prediction minimize gray zone Recommendations Patients fibrosis concomitant metabolic risk factors absence worsening metabolic risk factors monitored intervals 2 3 years C2 Patients fibrosis concomitant metabolic risk factors monitored annual basis combination noninvasive scores andor liver stiffness measurement C2 Patients cirrhosis undergo monitoring 6month intervals including surveillance hepatocellular carcinoma A2 PATIENT REPORTED OUTCOMES IN MAFLD M A F L D wa s d e m o n s t r t e d t o b e s s o c t e d low healthrelated quality life HRQoL independent demographics metabolic comorbidities149150 Instruments assessing patient reported outcomes PRO include questionnaires evaluate general HRQoL Chronic Liver Disease Questionnaire CLDQ Short Form36 SF36 EuroQoL 5Dimensions 5Level EQ5D5L diseasespecific questionnaires NASHCHECK CLDQNASH151153 Although questionnaires translated languages validated countries validated Egypt cultural variation influence PROs known Recommendations Patients MAFLD worse HRQoL physical fatigue mental scores compared patients causes chronic liver disease B2 Integration patient perspectives disease quality life satisfaction compliance lifestyle advice patientreported outcomes PRO crucial developing holistic patientcentered model care MAFLD B2 SPECIAL GROUPS Lean MAFLD Although overweightobesity classically associated development progression MAFLD recent metaanalysis estimated MAFLD population 408 nonobese 192 lean differences histological severity disease lean obese patients154155 Nonobese patients MAFLD worse outcome accelerated disease progression156158 Insulin resistance altered body fat distribution BMI better indicators MAFLD patients importance new diagnostic criteria MAFLD154 The management nonobese subjects MAFLD relies lifestyle intervention regular exercise controlling metabolic comorbidities irrespective baseline BMI A 35 weight reduction sufficient lean MAFLD In addition nonobese subjects likely maintain weight reduction normal liver enzymes long term compared obese subjects159 Recommendations MAFLD frequently exist nonobese subjects B1 Lifestyle intervention regular exercise effective treating MAFLD improving overall fitness metabolic comorbidities irrespective baseline BMI B1 Dual Etiologies As MAFLD longer diagnosis exclusion possible diagnose coexistence liver diseases HBV HCV meeting criteria diagnosis MAFLD plus diagnoses cause chronic liver diseases baseline followup diagnosed dual etiology liver disease These individuals likely different natural history response therapy liver disease single etiology24 With high prevalence rates MAFLD viral hepatitis Egypt expected disease entities frequently occur In regard recent study 10000 consecutive patients HCV Egypt estimated nearly half patients coexisting MAFLD group patients higher risk hepatic fibrosis compared HCV160 Saudi Journal Gastroenterology Volume 28 Issue 1 JanuaryFebruary 2022 13 Fouad et al Egyptian MAFLD guidelines Recommendations Patients liver diseases ALD viral hepatitis carefully evaluated possible concurrent MAFLD vice versa A1 Patients MAFLD advised avoid alcohol consume lowest possible B1 MAFLD management concomitant diseases standard guidelines diseases B1 Cured HCV Treated HBV Subjects MAFLD emerging key cause persistently abnormal liver tests continuing drive liver disease progression offset beneficial impact profound virological suppression sustained virological response poor outcomes individuals chronic HBV andor HCV infection endstage liver disease HCC burden dropout rate liver transplant waiting list161162 Treatment MAFLD group considered noninfected patients In addition multiple studies demonstrated direct acting antiviralsinduced SVR associated weight gain increased serum lipid levels hepatic steatosis163 Therefore group patients vulnerable MAFLDrelated complications Recommendations Patients cured HCV having profound HBV virological suppression MAFLD need monitoring increased risk progression cirrhosis development HCC extrahepaticrelated complications B1 The exact monitoring schedule defined patients followed according recommendations MAFLD single etiology B2 Deterioration lipid profiles increase weight hepatic steatosis frequently overlooked postSVR Clinicians actively monitor parameters intervene appropriate reduce cardiocerebral vascular disease risk B1 severity hepatic steatosis liver enzymes164 Another study showed direct effect Ramadan fasting improving noninvasive measures fibrosis inflammatory markers insulin sensitivity165 In addition preclinical animal studies human clinical trials demonstrated intermittent fasting widespectrum benefits health conditions including MAFLD166 Recommendations Ramadan fasting advisable plethoric beneficial effects patients MAFLD A2 MANAGEMENT OF MAFLDRELATED HCC Metabolic risk factor modification contribute optimum management patients MAFLDrelated HCC physical activity positive impact HCCrelated survival167 However sarcopenia reported prognostic factor patients HCC168175 careful consideration body composition including skeletal muscle mass body fat crucial recommending treating patients HCC particularly recommending physical activity T2DM risk factor HCC metformin demonstrated significantly reduce risk HCC MAFLD patients HbA1c levels 70134 extend survival HCC patients T2DM curative treatment HCC135 Thus MAFLDrelated HCC patients T2DM metformin lifestyle intervention recommended However prospective wellcontrolled randomized studies including Egyptian patients required strong recommendation Recommendations Metformin lifestyle intervention beneficial MAFLDrelated HCC patients particularly patients T2DM B1 Careful consideration sarcopenia prognostic factor appropriate nutritional therapy recommended C2 RAMADAN FASTING Restriction mealconsuming timing emerged potential promising dietary approach management obesity dysmetabolic diseases including MAFLD Ramadan fasting reported study Egypt 83 patients MAFLD lead reduction LIVER TRANSPLANTATION FOR MAFLD MAFLD emerging leading indication liver transplantation LT The related comorbidities MAFLD directly impact patient evaluation selection waitlist morbidity mortality eventually posttransplant 14 Saudi Journal Gastroenterology Volume 28 Issue 1 JanuaryFebruary 2022 Fouad et al Egyptian MAFLD guidelines outcomes Although LT radical treatment cirrhosis treat underlying comorbidities population maintained increased risk CVD postoperative morbidity LT176 Thus careful cardiovascular evaluation mandatory Survival MAFLDassociated liver transplant reported similar causes liver disease177 On contrary main causes mortality patients MAFLD following LT sepsis cardiovascular disease178 The increasing prevalence MAFLD general population corresponds directly increasing prevalence MAFLD deceased living donor pools The use steatotic livers associated increased risk graft failure andor impaired graft function179 The optimal regime MAFLD recipients unclear Strategies control associated comorbidities LT prioritized favorably impact waitlist mortality decrease rate recurrent novo MAFLD LT improve posttransplant outcome In addition immunosuppression including steroids calcineurins inhibitors cause worsen modifiable risk factors minimized Statins encouraged postLT dyslipidemia andor preexisting CVD associated survival benefit180 general population special populations MAFLD Fibrosis single major risk factor hepatic extrahepatic complications MAFLD numerous noninvasive tools assessment fibrosis available increasingly Holistic multidisciplinary patientcentered approaches needed provide optimal care patients MAFLD These models aim tackle entire spectrum disease includes resolution hepatic steatosis liver injury amelioration associated systemic metabolic milieu control accompanied comorbidities aggravate risk cardiovascular extrahepatic complications patientreported outcomes core Lifestyle intervention including dietary changes structured exercise remains holy grail management armamentarium therapeutic options expected available years In extreme spectrum disease bariatric metabolic surgery indicated MAFLD patients cirrhosis considered surveillance varices HCC Multiple gaps knowledge MAFLD identified joint effort stakeholders gathering evidence way forward adoption recommendations tackling growing burden Research priorities unmet needs field Recommendations Liver transplantation considered appropriately selected MAFLD patients decompensated liver disease HCC B1 Patients MAFLD high risk presence preexisting CVD thoroughly assessed prior listing transplantation followed B1 CONCLUSION The burden MAFLD rapidly increasing Egypt emerging leading cause chronic liver disease HCC liver transplantation In addition intimately associated numerous systemic complications T2DM CVD CKD multiple cancers In region dual etiology particularly viral hepatitis common challenging The Egyptian guideline document MAFLD aimed provide simple practical recommendations assessment management We recommend following research priorities improve MAFLDrelated health outcomes Egypt Serum tests risk stratification algorithms staging MAFLD validating cutoffs noninvasive scores fibrosis Egyptian MAFLD population Studies establish test efficacy task shifting referral pathways based MAFLD diagnostic criteria Identifying characteristics patients dual disease MAFLD HCV MAFLD HBV Characterization genetic architecture MAFLD region required Studies compare diagnostic accuracy cost effectiveness patient outcomes reported NAFLD MAFLD diagnostic criteria Egyptian cohorts Relative proportion global MAFLD population Egypt underrepresented ongoing clinical trials pharmaceutical treatments Thus clinical trials Egyptian populations necessary Saudi Journal Gastroenterology Volume 28 Issue 1 JanuaryFebruary 2022 15 Fouad et al Egyptian MAFLD guidelines Ethical approval Informed consent Nil Financial support sponsorship Nil Conflicts There conflicts REFERENCES 1 Harbour R Miller J A new grading recommendations evidence based guidelines BMJ 20013233346 2 Golzarand M Mirmiran P Jessri M Toolabi K Mojarrad M Azizi F Dietary trends Middle East North Africa An ecological study 1961 2007 Public Health Nutr 201215183544 3 Mahmood A Nutritional status anthropometric measurements women Egypt National Survey 20012002 Arab J Food Nutr 20041198107 WHO WHO MENA STEPS Surveys Final Report Geneva 2014 4 5 Esmat G ElSayed MH Hassany M Doss W Waked I National Committee Control Viral Hepatitis One step closer elimination hepatitis C Egypt Lancet Gastroenterol Hepatol 20183665 6 Galal OM The nutrition transition Egypt Obesity undernutrition food consumption context Public Health Nutr 200251418 7 TurkAdawi K Sarrafzadegan N Fadhil I Taubert K Sadeghi M Wenger NK et al Cardiovascular disease Eastern Mediterranean region Epidemiology risk factor burden Nat Rev Cardiol 20181510619 8 Azizi F Hadaegh F Hosseinpanah F Mirmiran P Amouzegar A Abdi H et al Metabolic health Middle East north Africa Lancet Diabetes Endocrinol 2019786679 9 Younossi Z Tacke F Arrese M Chander Sharma B Mostafa I Bugianesi E et al Global perspectives nonalcoholic fatty liver disease nonalcoholic steatohepatitis Hepatology 201969267282 10 Guthold R Stevens GA Riley LM Bull FC Worldwide trends insufficient physical activity 2001 2016 A pooled analysis 358 populationbased surveys 19 million participants Lancet Glob Health 20186e107786 11 Ng M Fleming T Robinson M Thomson B Graetz N Margono C et al Global regional national prevalence overweight obesity children adults 19802013 A systematic analysis Global Burden Disease Study 2013 Lancet 201438476681 12 Eslam M George J Genetic contributions NAFLD Leveraging shared genetics uncover systems biology Nat Rev Gastro Hepat 2020174052 13 Eslam M Valenti L Romeo S Genetics epigenetics NAFLD NASH Clinical impact J Hepatol 20186826879 14 Tomah S EID EM Abouelmagd MM Hassan AH Eldib AH Hamdy O 214LB Vibrationcontrolled transient elastography reveals alarming prevalence nonalcoholic fatty liver disease fibrosis young adults Egypt Am Diabetes Assoc 201968Supl 1 doi 102337db19214LB 15 Alkassabany YM Farghaly AG ElGhitany EM Prevalence risk factors predictors nonalcoholic fatty liver disease schoolchildren A hospitalbased study Alexandria Egypt Arab J Gastroenterol 2014157681 16 Fouad Y ea Prevalence metabolic associated fatty liver disease Egyptian Tertiary Care Center 2021 press 17 Abdel Alem S GY AbdAlla M Said E Fouad Y Capturing patient experience A qualitative study change NAFLD MAFLD realtime feedback J Hepatol 20217412612 NAFLD MAFLD increases awareness fatty liver disease primary care physicians specialists J Hepatol 20217412546 19 Alexander M Loomis AK FairburnBeech J van der Lei J DuarteSalles T PrietoAlhambra D et al Realworld data reveal diagnostic gap nonalcoholic fatty liver disease BMC Med 201816111 doi 101186s129160181103x 20 Standing HC Jarvis H Orr J Exley C Hudson M Kaner E et al GPs experiences perceptions early detection liver disease A qualitative study primary care Br J Gen Pract 201868e7439 21 Bertot LC Jeffrey GP Wallace M MacQuillan G Garas G Ching HL et al Nonalcoholic fatty liver diseaserelated cirrhosis commonly unrecognized associated hepatocellular carcinoma Hepatol Commun 201715360 22 Shiha G Alswat K Al Khatry M Sharara AI Örmeci N Waked I et al Nomenclature definition metabolicassociated fatty liver disease A consensus Middle East north Africa Lancet Gastroenterol Hepatol 202165764 23 Eslam M Sanyal AJ George J Toward accurate nomenclature fatty liver diseases Gastroenterology 20191575903 24 Eslam M Newsome PN Sarin SK Anstee QM Targher G RomeroGomez M et al A new definition metabolic dysfunctionassociated fatty liver disease An international expert consensus statement J Hepatol 2020732029 25 Eslam M Alkhouri N Vajro P Baumann U Weiss R Socha P et al Defining paediatric metabolic dysfunctionassociated fatty liver disease An international expert consensus statement Lancet Gastroenterol Hepatol 2021686473 26 Fouad Y Elwakil R Elsahhar M Said E Bazeed S Ali Gomaa A et al The NAFLDMAFLD debate Eminence vs evidence Liver Int 20214125560 27 Yamamura S Eslam M Kawaguchi T Tsutsumi T Nakano D Yoshinaga S et al MAFLD identifies patients significant hepatic fibrosis better NAFLD Liver Int 202040301830 28 Lee H Lee YH Kim SU Chang Kim H Metabolic dysfunctionassociated fatty liver disease incident cardiovascular disease risk A nationwide cohort study Clin Gastroenterol Hepatol 20202219213847e10 29 Tsutsumi T Eslam M Kawaguchi T Yamamura S Kawaguchi A Nakano D et al MAFLD better predicts progression atherosclerotic cardiovascular risk NAFLD Generalized estimating equation approach Hepatol Res 202151111528 30 MendezSanchez N Arrese M Gadano A Oliveira CP Fassio E Arab JP et al The Latin American Association Study Liver ALEH position statement redefinition fatty liver disease Lancet Gastroenterol Hepatol 202166572 31 Eslam M Sarin SK Wong VW Fan JG Kawaguchi T Ahn SH et al The Asian Pacific Association Study Liver clinical practice guidelines diagnosis management metabolic associated fatty liver disease Hepatol Int 202014889919 32 Zheng KI Fan JG Shi JP Wong VW Eslam M George J et al From NAFLD MAFLD A redefining moment fatty liver disease Chin Med J Engl 202013322713 33 Sepanlou SG Safiri S Bisignano C Ikuta KS Merat S Saberifiroozi M et al The global regional national burden cirrhosis cause 195 countries territories 19902017 A systematic analysis Global Burden Disease Study 2017 Lancet Gastroenterol Hepatol 2020524566 34 Dyson J Jaques B Chattopadyhay D Lochan R Graham J Das D et al Hepatocellular cancer The impact obesity type 2 diabetes multidisciplinary team J Hepatol 2014601107 35 Sharafi H Alavian SM The rising threat hepatocellular carcinoma Middle East North Africa region Results global burden disease study 2017 Clin Liver Dis Hoboken 20191421923 36 Fouad Y GA Kamal E Bazeed S Said E Gaber Y Temporal trends primary liver cancer caused specific aetiologies Egyptian Population 2021 press 18 Fouad Y Gomaa AA Semida N Abdel Ghany W Attia D Change 37 Younossi ZM Otgonsuren M Henry L Venkatesan C Mishra A 16 Saudi Journal Gastroenterology Volume 28 Issue 1 JanuaryFebruary 2022 Fouad et al Egyptian MAFLD guidelines Erario M et al Association nonalcoholic fatty liver disease NAFLD hepatocellular carcinoma HCC United States 2004 2009 Hepatology 201562172330 38 Stine JG Wentworth BJ Zimmet A Rinella ME Loomba R Caldwell SH et al Systematic review metaanalysis Risk hepatocellular carcinoma nonalcoholic steatohepatitis cirrhosis compared liver diseases Aliment Pharmacol Ther 201848696703 39 Eshraghian A Taghavi Seyed A Nikeghbalian S Kazemi K Shamsaeefar A Mansourian M et al Nonalcoholic steatohepatitis rapidly growing indication liver transplantation Iranian patients Iran J Gastroenterol Hepatol Govaresh 201722 doi 106002ect 20190205 40 Hasan F Daher HB The burden clinical care pathways nonalcoholic steatohepatitis Middle east Clin Liver Dis Hoboken 20191420711 41 Tariq R Axley P Singal AK Extrahepatic manifestations nonalcoholic fatty liver disease A review J Clin Exp Hepatol 202010817 42 Musso G Gambino R Tabibian JH Ekstedt M Kechagias S Hamaguchi M et al Association nonalcoholic fatty liver disease chronic kidney disease A systematic review metaanalysis Plos Med 201411e1001680 43 Targher G Bertolini L Rodella S Lippi G Zoppini G Chonchol M Relationship kidney function liver histology subjects nonalcoholic steatohepatitis Clin J Am Soc Nephrol 20105216671 44 Ong JP Pitts A Younossi ZM Increased overall mortality liverrelated mortality nonalcoholic fatty liver disease J Hepatol 20084960812 45 Angulo P Kleiner DE DamLarsen S Adams LA Bjornsson ES Charatcharoenwitthaya P et al Liver fibrosis histologic features associated longterm outcomes patients nonalcoholic fatty liver disease Gastroenterology 201514938997 e10 46 VilarGomez E CalzadillaBertot L WaiSun Wong V Castellanos M Allerde la Fuente R Metwally M et al Fibrosis severity determinant causespecific mortality patients advanced nonalcoholic fatty liver disease A multinational cohort study Gastroenterology 201815544357e17 47 Francque SM van der Graaff D Kwanten WJ Nonalcoholic fatty liver disease cardiovascular risk Pathophysiological mechanisms implications J Hepatol 20166542543 48 Wong VW Adams LA Ledinghen V Wong GL Sookoian S Noninvasive biomarkers NAFLD NASHcurrent progress future promise Nat Rev Gastroenterol Hepatol 20181546178 49 Hernaez R Lazo M Bonekamp S Kamel I Brancati FL Guallar E et al Diagnostic accuracy reliability ultrasonography detection fatty liver A metaanalysis Hepatology 201154108290 50 Karlas T Petroff D Sasso M Fan JG Mi YQ Lédinghen V et al Individual patient data metaanalysis controlled attenuation parameter CAP technology assessing steatosis J Hepatol 201766102230 51 Caussy C Alquiraish MH Nguyen P Hernandez C Cepin S Fortney LE et al Optimal threshold controlled attenuation parameter MRIPDFF gold standard detection hepatic steatosis Hepatology 201867134859 52 Wong VW Petta S Hiriart JB Cammà C Wong GL Marra F et al Validity criteria diagnosis fatty liver M probebased controlled attenuation parameter J Hepatol 20176757784 53 Caussy C Brissot J Singh S Bassirian S Hernandez C Bettencourt R et al Prospective sameday direct comparison controlled attenuation parameter M vs XL probe patients nonalcoholic fatty liver disease magnetic resonance imagingproton density fat fraction standard Clin Gastroenterol Hepatol 202018184250 e6 54 Caussy C Reeder SB Sirlin CB Loomba R Noninvasive quantitative assessment liver fat MRIPDFF endpoint NASH trials Hepatology 20186876372 55 Bedogni G Bellentani S Miglioli L Masutti F Passalacqua M Castiglione A et al The fatty liver index A simple accurate predictor hepatic steatosis general population BMC gastroenterology 2006633 doi 1011861471230X633 56 Xu Z Li H Tian S Wu J Li X Liu ZL et al Blood biomarkers diagnosis hepatic steatosis metabolic dysfunctionassociated fatty liver disease J Hepatol 20207312645 57 Wai CT Greenson JK Fontana RJ Kalbfleisch JD Marrero JA Conjeevaram HS et al A simple noninvasive index predict significant fibrosis cirrhosis patients chronic hepatitis C Hepatology 20033851826 58 Sterling RK Lissen E Clumeck N Sola R Correa MC Montaner J et al Development simple noninvasive index predict significant fibrosis patients HIVHCV coinfection Hepatology 200643131725 59 Angulo P Hui JM Marchesini G Bugianesi E George J Farrell GC et al The NAFLD fibrosis score A noninvasive identifies liver fibrosis patients NAFLD Hepatology 20074584654 60 Kaya E Bakir A Eren F Yilmaz Y The utility noninvasive scores nonalcoholic fatty liver disease patients normal elevated serum transaminases Hepatol Forum 202018 61 Alkayyali T Qutranji L Kaya E Bakir A Yilmaz Y Clinical utility noninvasive scores assessing advanced hepatic fibrosis patients type 2 diabetes mellitus A study biopsyproven nonalcoholic fatty liver disease Acta Diabetol 202057613618 62 Daniels SJ Leeming DJ Eslam M Hashem AM Nielsen MJ Krag A et al ADAPT An algorithm incorporating PROC3 accurately identifies patients NAFLD advanced fibrosis Hepatology 201969107586 63 Eslam M Wong GLH Hashem AM Chan HL Nielsen MJ Leeming DJ et al A sequential algorithm combining ADAPT liver stiffness stage metabolicassociated fatty liver disease hospitalbased primary care patients Am J Gastroenterol 202011698493 64 Lee HW Wong GL Kwok R Choi KC Chan CK Shu SS et al Serial transient elastography examinations monitor patients type 2 diabetes A prospective cohort study Hepatology 202072123041 65 Shiha GE ElEtreby S Bahgat M Hamed M El Sherbini M Ghoneem EA et al Chronic hepatitis C patients obesity Do need operators accurate evaluation liver stiffness Ann Hepatol 201817795801 Imajo K Kessoku T Honda Y Tomeno W Ogawa Y Mawatari H et al Magnetic resonance imaging accurately classifies steatosis fibrosis patients nonalcoholic fatty liver disease transient elastography Gastroenterology 201615062637e7 66 67 Park CC Nguyen P Hernandez C Bettencourt R Ramirez K Fortney L et al Magnetic resonance elastography vs transient elastography detection fibrosis noninvasive measurement steatosis patients biopsyproven nonalcoholic fatty liver disease Gastroenterology 2017152598607 e2 68 Chan WK Treeprasertsuk S Goh GB Fan JG Song MJ Charatcharoenwitthaya P et al Optimizing use nonalcoholic fatty liver disease fibrosis score fibrosis4 score liver stiffness measurement identify patients advanced fibrosis Clin Gastroenterol Hepatol 201917257080e37 69 Spinzi G Terruzzi V Minoli G Liver biopsy N Engl J Med 20013442030 70 Brunt EM Janney CG Di Bisceglie AM NeuschwanderTetri BA Bacon BR Nonalcoholic steatohepatitis A proposal grading staging histological lesions Am J Gastroenterol 199994246774 71 Kleiner DE Brunt EM Van Natta M Behling C Contos MJ Cummings OW et al Design validation histological scoring nonalcoholic fatty liver disease Hepatology Saudi Journal Gastroenterology Volume 28 Issue 1 JanuaryFebruary 2022 17 Fouad et al Egyptian MAFLD guidelines 200541131321 72 Bedossa P Poitou C Veyrie N Bouillot JL Basdevant A Paradis V et al Histopathological algorithm scoring evaluation liver lesions morbidly obese patients Hepatology 20125617519 73 Dulai PS Singh S Patel J Soni M Prokop LJ Younossi Z et al Increased risk mortality fibrosis stage nonalcoholic fatty liver disease Systematic review metaanalysis Hepatology 201765155765 74 DAmico G GarciaTsao G Pagliaro L Natural history prognostic indicators survival cirrhosis A systematic review 118 studies J Hepatol 20064421731 75 Scaglione S Kliethermes S Cao G Shoham D Durazo R Luke A et al The epidemiology cirrhosis United States A populationbased study J Clin Gastroenterol 2015496906 76 Wong VW Vergniol J Wong GL Foucher J Chan HL Le Bail B et al Diagnosis fibrosis cirrhosis liver stiffness measurement nonalcoholic fatty liver disease Hepatology 20105145462 77 Boursier J Vergniol J Guillet A Hiriart JB Lannes A Le Bail B et al Diagnostic accuracy prognostic significance blood fibrosis tests liver stiffness measurement FibroScan nonalcoholic fatty liver disease J Hepatol 2016655708 78 Ge PS Runyon BA Treatment patients cirrhosis New Engl J Med 201637576777 79 Chalasani N Wilson L Kleiner DE Cummings OW Brunt EM Unalp A et al Relationship steatosis grade zonal location histological features steatohepatitis adult patients nonalcoholic fatty liver disease J Hepatol 20084882934 80 Berzigotti A Merkel C Magalotti D Tiani C Gaiani S Sacerdoti D et al New abdominal collaterals ultrasound A clue progression portal hypertension Dig Liver Dis 200840627 81 Augustin S Pons M Maurice JB Bureau C Stefanescu H Ney M et al Expanding Baveno VI criteria screening varices patients compensated advanced chronic liver disease Hepatology 20176619808 82 Stafylidou M Paschos P Katsoula A Malandris K Ioakim K Bekiari E et al Performance Baveno VI expanded Baveno VI criteria excluding highrisk varices patients chronic liver diseases A systematic review metaanalysis Clin Gastroenterol Hepatol 201917174455e11 83 Zheng KI Liu C Li J Zhao L Zheng MH Wang F et al Validation Baveno VI expanded Baveno VI criteria identify highrisk varices patients MAFLDrelated compensated cirrhosis J Hepatol 20207315713 84 GarciaTsao G Abraldes JG Berzigotti A Bosch J Portal hypertensive bleeding cirrhosis Risk stratification diagnosis management 2016 practice guidance American Association study liver diseases Hepatology Baltimore Md 20176531035 85 Franchis R Baveno VIF Expanding consensus portal hypertension Report Baveno VI Consensus Workshop Stratifying risk individualizing care portal hypertension J Hepatol 20156374352 86 Eslam M Ampuero J Jover M AbdElhalim H Rincon D Shatat M et al Predicting portal hypertension variceal bleeding noninvasive measurements metabolic variables Ann Hepatol 20131242030 87 Loomba R Lim JK Patton H ElSerag HB AGA clinical practice update screening surveillance hepatocellular carcinoma patients nonalcoholic fatty liver disease Expert review Gastroenterology 2020158182230 88 Singal AG Lampertico P Nahon P Epidemiology surveillance hepatocellular carcinoma New trends J Hepatol 20207225061 89 Tzartzeva K Obi J Rich NE Parikh ND Marrero JA Yopp A et al Surveillance imaging alpha fetoprotein early detection hepatocellular carcinoma patients cirrhosis A metaanalysis Gastroenterology 2018154170618e1 90 Mikami S Tateishi R Hagiwara S Sato M Minami T Uchino K et al Tumor markers useful patients undergoing surveillance hepatocellular carcinoma unreliable results ultrasonography Hepatol Res 20154541522 91 Park HJ Jang HY Kim SY Lee SJ Won HJ Byun JH et al Nonenhanced magnetic resonance imaging surveillance tool hepatocellular carcinoma Comparison ultrasound J Hepatol 20207271824 92 Barbara L Benzi G Gaiani S Fusconi F Zironi G Siringo S et al Natural history small untreated hepatocellular carcinoma cirrhosis A multivariate analysis prognostic factors tumor growth rate patient survival Hepatology 1992161327 93 Santi V Trevisani F Gramenzi A Grignaschi A MiriciCappa F Del Poggio P et al Semiannual surveillance superior annual surveillance detection early hepatocellular carcinoma patient survival J Hepatol 2010532917 94 Mittal S ElSerag HB Sada YH Kanwal F Duan Z Temple S et al Hepatocellular carcinoma absence cirrhosis United States veterans associated nonalcoholic fatty liver disease Clin Gastroenterol Hepatol 20161412431e1 95 Estruch R Ros E SalasSalvadó J Covas MI Corella D Arós F et al Primary prevention cardiovascular disease Mediterranean diet New Engl J Med 2013368127990 96 Wijarnpreecha K Thongprayoon C Ungprasert P Coffee consumption risk nonalcoholic fatty liver disease A systematic review metaanalysis Eur J Gastroen Hepatol 201729e812 97 Dudekula A Rachakonda V Shaik B Behari J Weight loss nonalcoholic fatty liver disease patients ambulatory care setting largely unsuccessful correlates frequency clinic visits Plos One 201499e111808 doi 101371journalpone 0111808 98 Mazzotti A Caletti MT Brodosi L Di Domizio S Forchielli ML Petta S et al An internetbased approach lifestyle changes patients NAFLD Twoyear effects weight loss surrogate markers J Hepatol 201869115563 99 Long MT Massaro JM Hoffmann U Benjamin EJ Naimi TS Alcohol use associated hepatic steatosis persons presumed nonalcoholic fatty liver disease Clin Gastroenterol Hepatol 202018183141e5 100 Chang Y Cho YK Kim Y Sung E Ahn J Jung HS et al Nonheavy drinking worsening noninvasive fibrosis markers nonalcoholic fatty liver disease A cohort study Hepatology 2019696475 101 Blomdahl J Nasr P Ekstedt M Kechagias S Moderate alcohol consumption associated advanced fibrosis nonalcoholic fatty liver disease shows synergistic effect type 2 diabetes mellitus Metabolism 2021115154439 102 Aberg F HeleniusHietala J Puukka P Farkkila M Jula A Interaction alcohol consumption metabolic syndrome predicting severe liver disease general population Hepatology 20186721419 103 Ascha MS Hanouneh IA Lopez R Tamimi TAR Feldstein AF Zein NN The incidence risk factors hepatocellular carcinoma patients nonalcoholic steatohepatitis Hepatology 20105119728 104 Abdelbasset WK Tantawy SA Kamel DM Alqahtani BA Soliman GS A randomized controlled trial effectiveness 8week highintensity interval exercise intrahepatic triglycerides visceral lipids healthrelated quality life diabetic obese patients nonalcoholic fatty liver disease Medicine 201998e14918 105 Oh S So R Shida T Matsuo T Kim B Akiyama K et al Highintensity aerobic exercise improves hepatic fat content stiffness sedentary obese men nonalcoholic fatty liver disease Sci RepUk 2017743029 doi 101038srep43029 106 Saran U Humar B Kolly P Dufour JF Hepatocellular carcinoma lifestyles J Hepatol 20166420314 107 Garber CE Blissmer B Deschenes MR Franklin BA Lamonte MJ Lee IM et al Quantity quality exercise developing maintaining cardiorespiratory musculoskeletal neuromotor fitness apparently healthy adults Guidance prescribing exercise Med 18 Saudi Journal Gastroenterology Volume 28 Issue 1 JanuaryFebruary 2022 Fouad et al Egyptian MAFLD guidelines Sci Sports Exerc 201143133459 108 Zhang HJ He J Pan LL Ma ZM Han CK Chen CS et al Effects moderate vigorous exercise nonalcoholic fatty liver disease A randomized clinical trial JAMA Intern Med 2016176107482 109 Abdelbasset WK Tantawy SA Kamel DM Alqahtani BA Elnegamy TE Soliman GS et al Effects highintensity interval moderateintensity continuous aerobic exercise diabetic obese patients nonalcoholic fatty liver disease A comparative randomized controlled trial Medicine 202099e19471 doi 101097 MD0000000000019471 110 Seki Y Kakizaki S Horiguchi N Hashizume H Tojima H Yamazaki Y et al Prevalence nonalcoholic steatohepatitis Japanese patients morbid obesity undergoing bariatric surgery J Gastroenterol 2016512819 111 Subichin M Clanton J Makuszewski M Bohon A Zografakis JG Dan A Liver disease morbidly obese A review 1000 consecutive patients undergoing weight loss surgery Surg Obes Relat Dis 20151113741 112 Salman MA Salman AA Omar HS Abdelsalam A Mostafa MS Tourky M et al Longterm effects oneanastomosis gastric bypass liver histopathology NAFLD cases A prospective study Surg Endosc 2020351889941 113 Salman AA Sultan AA Abdallah A Abdelsalam A Mikhail HM Tourky M et al Effect weight loss induced laparoscopic sleeve gastrectomy liver histology serum adipokine levels J Gastroen Hepatol 202035176973 114 AguilarOlivos NE AlmedaValdes P AguilarSalinas CA Uribe M MendezSanchez N The role bariatric surgery management nonalcoholic fatty liver disease metabolic syndrome Metabolism 2016651196207 115 Clanton J Subichin M The Effects Metabolic Surgery fatty liver disease nonalcoholic steatohepatitis Surg Clin North Am 20169670315 116 Hafeez S Ahmed MH Bariatric surgery potential treatment nonalcoholic fatty liver disease A future treatment choice chance J Obes 20132013 doi 101155201383927 117 Lassailly G Caiazzo R NtandjaWandji LC Gnemmi V Baud G Verkindt H et al Bariatric surgery provides longterm resolution nonalcoholic steatohepatitis regression fibrosis Gastroenterology 20201591290301 118 Mosko JD Nguyen GC Increased perioperative mortality following bariatric surgery patients cirrhosis Clin Gastroenterol Hepatol 20119897901 119 Salman MA Mikhail HM Nafea MA Sultan AA Elshafey HE Tourky M et al Impact laparoscopic sleeve gastrectomy fibrosis stage patients childA NASHrelated cirrhosis Surg Endosc 202035126977 120 Salomone F Sharaiha RZ Boškoski I Endoscopic bariatric metabolic therapies nonalcoholic fatty liver disease Evidence perspectives Liver Int 20204012628 121 Chalasani N Younossi Z Lavine JE Charlton M Cusi K Rinella M et al The diagnosis management nonalcoholic fatty liver disease Practice guidance American Association Study Liver Diseases Hepatology 20186732857 122 European Association Study Liver European Association Study Diabetes European Association Study Obesity EASLEASDEASO Clinical Practice Guidelines management nonalcoholic fatty liver disease J Hepatol 2016641388402 123 Sanyal AJ Chalasani N Kowdley KV McCullough A Diehl AM Bass NM et al Pioglitazone vitamin E placebo nonalcoholic steatohepatitis New Engl J Med 2010362167585 124 Cusi K Orsak B Bril F Lomonaco R Hecht J OrtizLopez C et al Longterm pioglitazone treatment patients nonalcoholic steatohepatitis prediabetes type 2 diabetes mellitus A randomized trial Ann Intern Med 201616530515 A placebocontrolled trial pioglitazone subjects nonalcoholic steatohepatitis New Engl J Med 20063552297307 126 Aithal GP Thomas JA Kaye PV Lawson A Ryder SD Spendlove I et al Randomized placebocontrolled trial pioglitazone nondiabetic subjects nonalcoholic steatohepatitis Gastroenterology 2008135117684 127 Bril F Biernacki DM Kalavalapalli S Lomonaco R Subbarayan SK Lai J et al Role vitamin E nonalcoholic steatohepatitis patients type 2 diabetes A randomized controlled trial Diabetes Care 20194214818 128 Mehtala J Khanfir H Bennett D Ye Y Korhonen P Hoti F Pioglitazone use risk bladder cancer A systematic literature review metaanalysis observational studies Diabetol Int 2019102436 129 PortilloSanchez P Bril F Lomonaco R Barb D Orsak B Bruder JM et al Effect pioglitazone bone mineral density patients nonalcoholic steatohepatitis A 36month clinical trial J Diabetes 20191122331 130 Haukeland JW Konopski Z Eggesbo HB von Volkmann HL Raschpichler G Bjøro K et al Metformin patients nonalcoholic fatty liver disease A randomized controlled trial Scand J Gastroenterol 20094485360 131 Musso G Gambino R Cassader M Pagano G A metaanalysis randomized trials treatment nonalcoholic fatty liver disease Hepatology 20105279104 132 Lavine JE Schwimmer JB Van Natta ML Molleston JP Murray KF Rosenthal P et al Effect vitamin E metformin treatment nonalcoholic fatty liver disease children adolescents The TONIC randomized controlled trial JAMA 2011305165968 133 Li Y Liu L Wang B Wang J Chen D Metformin nonalcoholic fatty liver disease A systematic review metaanalysis Biomed Rep 201315764 134 VilarGomez E CalzadillaBertot L WaiSun Wong V Castellanos M Allerde la Fuente R Eslam M et al Type 2 diabetes metformin use associate outcomes patients nonalcoholic steatohepatitisrelated ChildPugh A cirrhosis Clin Gastroenterol Hepatol 20211913645e6 135 Zhou J Ke Y Lei X Wu T Li Y Bao T et al Metaanalysis The efficacy metformin antihyperglycemic agents prolonging survival hepatocellular carcinoma patients type 2 diabetes Ann Hepatol 2020193208 136 Harrison SA Torgerson S Hayashi P Ward J Schenker S Vitamin E vitamin C treatment improves fibrosis patients nonalcoholic steatohepatitis Am J Gastroenterol 200398248590 137 Hoofnagle JH Van Natta ML Kleiner DE Clark JM Kowdley KV Loomba R et al Vitamin E changes serum alanine aminotransferase levels patients nonalcoholic steatohepatitis Aliment Pharmacol Ther 20133813443 138 Sato K Gosho M Yamamoto T Kobayashi Y Ishii N Ohashi T et al Vitamin E beneficial effect nonalcoholic fatty liver disease A metaanalysis randomized controlled trials Nutrition 20153192330 139 Sarkhy AA AlHussaini AA Nobili V Does vitamin E improve outcomes pediatric nonalcoholic fatty liver disease A systematic review metaanalysis Saudi J Gastroenterol 20142014353 140 Amanullah I Khan YH Anwar I Gulzar A Mallhi TH Raja AA Effect vitamin E nonalcoholic fatty liver disease A systematic review metaanalysis randomised controlled trials Postgrad Med J 20199560111 141 VilarGomez E Vuppalanchi R Gawrieh S Ghabril M Saxena R Cummings OW et al Vitamin E improves transplantfree survival hepatic decompensation patients nonalcoholic steatohepatitis advanced fibrosis Hepatology 202071495509 142 Klein EA Thompson IM Jr Tangen CM Crowley JJ Lucia MS Goodman PJ et al Vitamin E risk prostate cancer The selenium vitamin E cancer prevention trial SELECT JAMA 2011306154956 125 Belfort R Harrison SA Brown K Darland C Finch J Hardies J et al 143 Eslami L Merat S Malekzadeh R NasseriMoghaddam S Aramin H Saudi Journal Gastroenterology Volume 28 Issue 1 JanuaryFebruary 2022 19 Fouad et al Egyptian MAFLD guidelines Statins nonalcoholic fatty liver disease nonalcoholic steatohepatitis Cochrane Database Syst Rev 2013CD008623 doi 10100214651858CD008623pub2 144 Athyros VG Tziomalos K Gossios TD Griva T Anagnostis P Kargiotis K et al Safety efficacy longterm statin treatment cardiovascular events patients coronary heart disease abnormal liver tests Greek Atorvastatin Coronary Heart Disease Evaluation GREACE Study A posthoc analysis Lancet 2010376191622 145 Eslam M Alvani R Shiha G Obeticholic acid Towards approval NASH Lancet 201939421313 146 Taylor RS Taylor RJ Bayliss S Hagström H Nasr P Schattenberg JM et al Association fibrosis stage outcomes patients nonalcoholic fatty liver disease A systematic review metaanalysis Gastroenterology 2020158161125e12 147 Kaya E Bakir A Kani HT Demirtas CO Keklikkiran C Yilmaz Y Simple noninvasive scores clinically useful exclude predict advanced fibrosis A study Turkish patients biopsyproven nonalcoholic fatty liver disease Gut Liver 20191448691 148 Jafarov F Kaya E Bakir A Eren F Yilmaz Y The diagnostic utility fibrosis4 nonalcoholic fatty liver disease fibrosis score combined liver stiffness measurement fibroscan assessment advanced liver fibrosis A biopsyproven nonalcoholic fatty liver disease study Eur J Gastroen Hepat 2020326429 149 Younossi ZM Stepanova M Anstee QM Lawitz EJ WaiSun Wong V RomeroGomez M et al Reduced patientreported outcome scores associate level fibrosis patients nonalcoholic steatohepatitis Clin Gastroenterol Hepatol 201917255260e10 150 Huber Y Boyle M Hallsworth K Tiniakos D Straub BK Labenz C et al Healthrelated quality life nonalcoholic fatty liver disease associates hepatic inflammation Clin Gastroenterol Hepatol 201917208592 e1 151 Younossi ZM Patientreported outcomes economic effects nonalcoholic fatty liver disease nonalcoholic steatohepatitis The value proposition Hepatology 201868240512 152 Doward L Balp MM Twiss J Slota C Cryer D Langford A et al Measuring matters patients The development NASHCHECK new patientreported outcome instrument nonalcoholic steatohepatitis J Hepatol 201868S570 153 Younossi ZM Stepanova M Henry L Racila A Lam B Pham HT et al A diseasespecific quality life instrument nonalcoholic fatty liver disease nonalcoholic steatohepatitis CLDQNAFLD Liver Int 201737120918 154 Eslam M Fan JG MendezSanchez N Nonalcoholic fatty liver disease nonobese individuals The impact metabolic health Lancet Gastroenterol Hepatol 202057135 155 Ye Q Zou B Yeo YH Li J Huang DQ Wu Y et al Global prevalence incidence outcomes nonobese lean nonalcoholic fatty liver disease A systematic review metaanalysis Lancet Gastroenterol Hepatol 2020573952 156 Dela Cruz AC Bugianesi E George J Day CP Liaquat H Charatcharoenwitthaya P et al Characteristics longterm prognosis lean patients nonalcoholic fatty liver disease Gastroenterology 2014146S909 157 Chen F Esmaili S Rogers G Bugianesi E Petta S Marchesini G et al Lean NAFLD A distinct entity shaped differential metabolic adaptation Hepatology 202071121327 158 Eslam M Chen F George J NAFLD Lean Asians Clin Liver Dis Hoboken 2021162403 159 Wong VWS Wong GLH Chan RSM Shu SS Cheung BH Li LS et al Beneficial effects lifestyle intervention nonobese patients nonalcoholic fatty liver disease J Hepatol 201869134956 160 Attia D FY Abdel Razik W ElAkel W Eslam M Waked I Metabolic associated fatty liver disease chronic hepatitis C patients 2021 press 161 Noureddin M Wong MM Todo T Lu SC Sanyal AJ Mena EA Fatty liver hepatitis C patients postsustained virological response directacting antivirals World J Gastroenterol 201824126977 162 Peleg N Issachar A Arbib OS CohenNaftaly M Braun M Leshno M et al Liver steatosis strong predictor mortality cancer chronic hepatitis B regardless viral load JHEP Rep 20191916 163 Fouad Y Lazarus JV Negro F PeckRadosavljevic M Sarin SK Ferenci P et al MAFLD considerations global hepatitis C elimination effort An international perspective Aliment Pharmacol Ther 20215310809 164 Ebrahimi S Gargari BP Aliasghari F Asjodi F Izadi A Ramadan fasting improves liver function total cholesterol patients nonalcoholic fatty liver disease Int J Vitam Nutr Res 20209095102 165 Mari A Khoury T Baker M Baker A Mahamid M The impact Ramadan fasting fatty liver disease severity A retrospective case control study Israel Isr Med Assoc J 202123948 166 Cabo R Mattson MP Effects intermittent fasting health aging disease New Engl J Med 2019381254151 167 Hashida R Kawaguchi T Koya S Hirota K Goshima N Yoshiyama T et al Impact cancer rehabilitation prognosis patients hepatocellular carcinoma Oncol Lett 202019235567 168 Harimoto N Shirabe K Yamashita YI Ikegami T Yoshizumi T Soejima Y et al Sarcopenia predictor prognosis patients following hepatectomy hepatocellular carcinoma Br J Surg 2013100152330 169 Fujiwara N Nakagawa H Kudo Y Tateishi R Taguri M Watadani T et al Sarcopenia intramuscular fat deposition visceral adiposity independently predict outcomes hepatocellular carcinoma J Hepatol 20156313140 170 Harimoto N Yoshizumi T Shimokawa M Sakata K Kimura K Itoh S et al Sarcopenia poor prognostic factor following hepatic resection patients aged 70 years older hepatocellular carcinoma Hepatol Res 201646124755 171 Nishikawa H Nishijima N Enomoto H Sakamoto A Nasu A Komekado H et al Prognostic significance sarcopenia patients hepatocellular carcinoma undergoing sorafenib therapy Oncol Lett 201714163747 172 Ha Y Kim D Han S Chon YE Lee YB Kim MN et al Sarcopenia predicts prognosis patients newly diagnosed hepatocellular carcinoma independent tumor stage liver function Cancer Res Treat 20185084351 173 Imai K Takai K Watanabe S Hanai T Suetsugu A Shiraki M et al Sarcopenia impairs prognosis patients hepatocellular carcinoma The role liver functional reserve tumorrelated factors loss skeletal muscle volume Nutrients 201791054 doi 103390nu9101054 174 Takada H Kurosaki M Nakanishi H Takahashi Y Itakura J Tsuchiya K et al Impact presarcopenia sorafenib treatment advanced hepatocellular carcinoma PLoS One 201813e0198812 175 Mardian Y Yano Y Ratnasari N Choridah L Wasityastuti W Setyawan NH et al Sarcopenia intramuscular fat deposition associated poor survival Indonesian patients hepatocellular carcinoma A retrospective study BMC Gastroenterol 201919229 176 Yalamanchili K Saadeh S Klintmalm GB Jennings LW Davis GL Nonalcoholic fatty liver disease liver transplantation cryptogenic cirrhosis nonalcoholic fatty liver disease Liver Transpl 2010164319 177 Wang X Li J Riaz D Shi G Liu C Dai Y Outcomes liver transplantation nonalcoholic steatohepatitis A systematic review metaanalysis Clin Gastroenterol Hepatol 201412394402e1 178 Neal DA Tom BD Luan JA Wareham NJ Gimson AE Delriviere LD et al Is disparity risk incidence cardiovascular disease liver transplant Transplantation 200477939 179 McCormack L Dutkowski P ElBadry AM Clavien PA Liver transplantation fatty livers Always feasible J Hepatol 201154105562 180 Patel SS Rodriguez VA Siddiqui MB Faridnia M Lin FP Chandrakumaran A et al The impact coronary artery disease statins survival liver transplantation Liver Transpl 201925151423 20 Saudi Journal Gastroenterology Volume 28 Issue 1 JanuaryFebruary 2022 Fouad et al Egyptian MAFLD guidelines